|
業務類別
|
Biotechnology |
|
業務概覽
|
Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorderswith high unmet medical need. |
| 公司地址
| 100 Summit Drive, Burlington, MA, USA, 01803 |
| 電話號碼
| +1 781 439-5551 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.neuphoriatx.com |
| 員工數量
| 24 |
| Mr. Timothy M. Cunningham |
Chief Financial Officer |
-- |
29/09/2025 |
| Dr. Spyros Papapetropoulos, M.D.,PhD |
Director, President and Chief Executive Officer |
美元 550.00K |
30/10/2025 |
|
|
| Dr. Stephen K. Doberstein, PhD |
Independent Director |
17/12/2025 |
| Mr. Peter Miles Davies |
Independent Director |
30/10/2025 |
| Mr. Alan Fisher |
Chairman of the Board |
30/10/2025 |
| Dr. Jane Ryan, PhD |
Independent Director |
30/10/2025 |
| Mr. David Wilson |
Director |
30/10/2025 |
| Dr. Spyros Papapetropoulos, M.D.,PhD |
Director, President and Chief Executive Officer |
30/10/2025 |
| Ms. Kimberly Smith |
Independent Director |
17/12/2025 |
|
|
|
|
